PDS Biotechnology (PDSB) Projected to Post Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 12:30 PM ET.

PDS Biotechnology Price Performance

Shares of PDSB stock opened at $0.65 on Thursday. PDS Biotechnology has a 1 year low of $0.60 and a 1 year high of $1.92. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. The firm’s 50 day moving average is $0.77 and its 200-day moving average is $0.89. The firm has a market capitalization of $34.02 million, a price-to-earnings ratio of -0.79 and a beta of 1.20.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in PDS Biotechnology in the fourth quarter valued at approximately $25,000. Geode Capital Management LLC grew its holdings in PDS Biotechnology by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after acquiring an additional 38,399 shares during the period. Marshall Wace LLP bought a new stake in shares of PDS Biotechnology during the 2nd quarter valued at $91,000. Jane Street Group LLC acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at $92,000. Finally, Susquehanna International Group LLP lifted its stake in shares of PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares during the period. 26.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. B. Riley Financial dropped their price objective on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, November 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.